CDC Says Over 556,208 Pfizer/BioNTech COVID-19 Shots Administered In Week 1 Of Inoculation Drive
Portfolio Pulse from Aditya Raghunath
The CDC reports that over 556,208 doses of the Pfizer/BioNTech COVID-19 vaccine have been administered in the first week of the U.S. vaccination drive. The FDA has approved vaccines from Pfizer/BioNTech and Moderna, with the latter's vaccine cleared for use by the CDC. AstraZeneca and Johnson & Johnson have potential candidates in phase three trials.
December 21, 2020 | 7:39 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
AstraZeneca's COVID-19 vaccine candidate is in phase three trials, indicating potential future approval and market entry.
While AstraZeneca's vaccine is still in phase three trials, its mention indicates potential future developments. However, the immediate impact is neutral as it has not yet received approval.
CONFIDENCE 70
IMPORTANCE 50
RELEVANCE 50
NEUTRAL IMPACT
Johnson & Johnson's Janssen Pharmaceuticals unit has a COVID-19 vaccine candidate in phase three trials, indicating potential future market entry.
Johnson & Johnson's vaccine candidate is in phase three trials, suggesting potential future developments. The immediate impact is neutral as it has not yet received approval.
CONFIDENCE 70
IMPORTANCE 50
RELEVANCE 50
POSITIVE IMPACT
BioNTech, in partnership with Pfizer, has administered over 556,208 doses of their COVID-19 vaccine in the first week, indicating a successful start to the vaccination campaign.
The administration of over 556,208 doses in the first week is a positive indicator for BioNTech, suggesting strong demand and effective distribution of their vaccine.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 85
POSITIVE IMPACT
Moderna's COVID-19 vaccine has received FDA emergency use authorization, with the CDC clearing it for use, paving the way for its distribution in the U.S.
The FDA's emergency use authorization and CDC clearance for Moderna's vaccine are significant regulatory milestones, likely to positively impact Moderna's stock as distribution begins.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Pfizer's COVID-19 vaccine, developed with BioNTech, has seen over 556,208 doses administered in the first week. The FDA's approval and the CDC's report highlight the vaccine's initial success.
The successful administration of over 556,208 doses in the first week indicates strong initial uptake and distribution, which is positive for Pfizer's stock. The FDA's approval and CDC's report further support this positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90